US › Healthcare

Fulgent Genetics Inc (FLGT)

US · Healthcare · Diagnostics & Research

$23.74+27.22%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$85.4M

Revenue YoY

+4.4%

Net profit

$-29.5M

EPS

$-0.88

EPS estimate

$-0.79

Net margin

-34.6%

EPS came in at -0.88 against a street estimate of -0.79 — a miss of 11.4%.

Key statistics

Market cap

$513.4M

Forward P/E

7.7

P/B

0.51

Book value

$35.78

EPS (TTM)

$-2.82

52-week high

$31.04

52-week low

$13.46

50-day MA

$20.73

200-day MA

$19.20

Beta

1.02

Analyst view

Analysts rate Fulgent Genetics Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $19.00.

Shareholding

Insiders

37.71%

Institutions

57.96%

Largest institutional holders

Fund	Stake
BlackRock Inc	8.31%
Acadian Asset Management LLC	3.70%
Vanguard Capital Management, LLC	2.87%
Jacobs Levy Equity Management, Inc.	2.84%
JPMorgan Chase & Co	2.75%
Diametric Capital, LP	2.54%
Ameriprise Financial Inc	2.44%
Dimensional Fund Advisors, Inc.	2.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fulgent Genetics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.